What an AI agent reads on Oslo Myeloma Center
An assistant's crawler fetches the page once, without running JavaScript, and reads the text, the structured data and the links. Below is what it gets from ous-research.no, taken from the copy the scanner kept.
2,666
characters of text without JavaScript
none
structured data for the business
0
of 3 AI crawlers turned away at the edge
The words an agent gets
Title: OUH - Oslo Myeloma Center · language en. First 1,800 of 2,666 characters:
OUH - Oslo Myeloma Center ❭ Research by medical division ❭ Cancer Medicine ❭ Department of Haematology ❭ Oslo Myeloma Center (Schjesvold) Oslo Myeloma Center F. SchjesvoldGroup leaderGroup leader: Fredrik Schjesvold, MD, PhD In the media About our research: Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordic region. In January 2026, our center was awarded Clinical Trial Center of the Year (Årets Senter) in Norway. The center contributes to approximately 5% of all global industry-sponsored myeloma trials. Since 2015, Oslo Myeloma Center has enrolled over 1019 patients in 67 clinical studies, including newly diagnosed and relapsed/refractory patients across Phase 1, 2, 3 and 4 trials.Read more about our research August 2025 October 2023 Ongoing trials Ongoing and upcoming trials Scroll to top Home Department of Haematology Oslo Myeloma Center (Schjesvold) Group members Associated research groups Trials Publications In the media About our research Recent publications Merz M, Souto Filho JT, Voorhees PM, Einsele H, Schjesvold F, Scheffer Cliff ER, Mateos MV, Hungria V, Cohen YC, de Larrea CF, Beksac M, Landgren O, Usmani SZ, Costa LJ, Gagelmann N (2026) T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis J Hematol Oncol, 19 (1) DOI 10.1186/s13045-026-01850-2, PubMed 42844619 Lonial S, Dimopoulos MA, Gavriatopoulou M, Kim K, Min CK, Oriol A, Moreira CCC, Quach H, Qiu L, Xia Z, Schjesvold F, Casas-Avilés I, Xu Y, Hungria V, Seval GC, Fang B, Kyriakou C, Prince HM, Zhuang J, Lin HC, Mateos MV, Špička I, Maiolino A, Vural F, Basu S, Dytfeld D, Fu C, Ho PJ, Joseph N, Low M et al. (2026) Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone
What it can say about the business
| A business type in JSON-LD | no |
| Name | no |
| Telephone | no |
| Address | no |
| Opening hours | no |
| Menu or price list | nothing |
| Cuisine in structured data | no |
| JSON-LD blocks | 0 |
The links it would act on
No booking or ordering link found. An agent has nothing to act on.
Everything here comes from fetching the homepage once as a crawler. The report turns it into a score and a list of fixes, with code to paste.